Long-term treatment of persistent disseminated Nocardia cyriacigeorgica infection  by Özgenç, Onur et al.
b r a z j i n f e c t d i s . 2 0 1 4;1  8(5):556–560
The Brazilian Journal of
INFECTIOUS  DISEASES
www.elsev ier .com/ locate /b j id
Case report
Long-term  treatment  of  persistent  disseminated
Nocardia cyriacigeorgica  infection
Onur Özgenc¸a,∗, Meltem Avcıb, Alpay Arıb, I˙smail Yunus C¸ elebi c, Seher Ayten Cos¸kunerb
a Dokuz Eylul University Hospital, Clinics of Infectious Diseases, Karsiyaka, Izmir, Turkey
b Izmir Bozyaka Teaching and Research Hospital, Clinics of Infectious Diseases and Clinical Microbiology, Izmir, Turkey
c Bursa Inegol Public Hospital, Clinics of Infectious Diseases, Bursa, Turkey
a  r  t  i  c  l  e  i  n  f  o
Article history:
Received 29 January 2014
Accepted  11 March 2014
Available  online 13 May 2014
Keywords:
a  b  s  t  r  a  c  t
In this paper a disseminated persistent Nocardia cyriacigeorgica infection in an immunocom-
petent  patient is described. The patient’s long-term treatment, as well as its implications for
managing similar cases in the future, is emphasized. Presenting with high fever, multiple
nodules,  and ulcerative cutaneous lesions of body sites, the patient was treated with various
antimicrobials.  Under combined therapy, empyema and arthritis, leading to disseminated
nocardiosis,  were seen. The overall treatment course was 28 months. It can be concludedNocardia cyriacigeorgica
Chronic  infection
Treatment
that  the choice of the antibiotics and optimal duration of treatment are uncertain; therefore
the  treatment of nocardiosis requires expertise.
ules,  and ulcerative lesions of various body sites. She had no
underlying  diseases and only had scratches on her hand as
a  probable indicator of occupational trauma. Previously she
had  been treated for cellulitis and lymphedema in the ward
© 2014 Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-NDIntroduction
Herein we  describe a case of disseminated Nocardia cyr-
iacigeorgica infection, a recently identiﬁed species, in an
immunocompetent patient. The infection was  most likely
acquired  from direct inoculation of body surfaces as a result of
occupational  exposure. Different factors that may  have con-
tributed  to the long-term treatment of the disease and the
subsequent  relapse in this patient in spite of in vitro suscepti-
bility  of the isolate to all drugs administered are discussed.∗ Corresponding author.
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Patient  clinical  status
A 45-year-old woman, who has been working as a farmer
was  hospitalized with symptoms of high fever, multiple nod-r (O. Özgenc¸).
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dFig. 1 – The ulcerative lesion on the patient’s chin.
f internal medicine for two weeks and then moved  to the
nfectious  diseases clinic. She presented with fever (38.5◦ C),
ultiple  cutaneous, erythematous, edematous nodules, and
bscesses  over the left breast and on the left upper and lower
xtremities.  Similar edematous or ulcerative lesions were later
een under the chin (Fig. 1), on dorso-thorocal, and lom-
ar  regions. The lower extremities were  edematous. Under
herapy  some partial resolution of cutaneous lesions were
bserved.  Also, painful new nodules appeared in the following
wo  weeks and some existing nodules continued to expand in
ize. The nodules and ulcerative lesions varied in size from 2
o 12 cm and were  tender and erythematous. Remarkable res-
lution of some cutaneous and subcutaneous lesions (Fig. 2)
as  seen. Some of the pre-existing nodules have ulcerated
nd  that underwent surgical debridement. Despite in vitro
usceptibility of the isolate to all drugs administered, new
yogenic  abscesses, empyema  of the thorax, and respiratory
istress  have ensued. The chest radiograph showed left-sided
leural  collection. Thoracocentesis and surgical drainage were
ig. 2 – The scars of the healed lesions on the
orso-thorocal region of the body.Fig. 3 – The cutaneous nodule on the lower extremity.
performed; pleural ﬂuid was  obtained for culture. Pleural
empyema  also occurred on the right side of the lung within
two  weeks; again surgical drainage was  performed. Three
months  after admission, empyema  and skin nodules had
fully  resolved with scarring. Under suppression maintenance
therapy, relapsing fever and cutaneous nodules (Fig. 3) have
ensued  which were later cleared by an additional two months
of  treatment. Six months later with combined antimicrobial
therapy, the patient was discharged from the hospital on doxy-
cycline  maintenance monotherapy. Arthritis of the right knee
and  ankle, high fever, and new cutaneous lesions developed
within  a month of hospital discharge and the patient was
again  hospitalized. The patient presented with high fever and
new  nodules. A new drug (linezolid) which was not on the
market  at that time was initiated. After clinical and laboratory
response to therapy at the end of one year, some ﬂuctuating
cutaneous symptoms had appeared for a period of ten more
months.  The patient then remained healthy in the following
three  years of follow-up (Table 1).
Laboratory  methods  for  diagnosis
Erythrocyte sedimentation rate (EST) was  10 mm/h, blood
count  was  as follows: leukocyte 7070 mm–3, Hb 9.1 g/L, Ht
32.5,  platelet 419,000 mm–3. CRP was 9.7 mg/dL. All bio-
chemical tests except moderate hypoproteinemia (albumin
3  mg/dL, globulin 1.9 mg/dL) were within normal ranges.
Chest  radiograph and urinalysis were also normal. Gram-
stained  preparations of pus from ulcerative lesions showed
mostly  Gram-positive small rods and coccoid fragments
within leukocytes. Ziehl–Nielsen stained preparations were
negative.  Bacteriological culture showed no growth. Later,
abscesses  material and pleural ﬂuid cultured on Myco/F-Lytic
BACTEC liquid medium (brain–heart and 7H9 Middlebrook)
and Loewenstein–Jenseen medium grew presumptive Nocar-
dia  species in a pure culture within one week. Branching rods
were  seen in Ziehl–Nielsen with 1% sulfuric acid (modiﬁed
Kinyoun technique) stained preparations, a typical feature
of  nocardiae.1–4 The microorganism was conﬁrmed as N.
cyriacigeorgica at the reference laboratory in France. The
strain  was  reported as sensitive to amikacin, gentamicin,
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Table 1 – Features of disseminated Nocardia cyriacigeorgica infection.
Symptoms Laboratory ﬁndings Treatment Duration of therapy Clinical outcome
High fever, new nodules ESR 10 mm/h, WBC 7070 mm–3, Hb
13.8 g/L, CRP 9.7 mg/dL
Ceftizoxime 6 g/d + clindamycin
1800  mg/d
1st  ⇒ 14th days Partial resolution, new lesion (chin)
Ulcerative lesion under chin Gram stain: small rods and coccus TMP/SXT 10 mg/kg/day + Imipenem
2 g/day
14th  ⇒ 45th days New lesions (dorso-thorocal region) bone
marrow suppression (WBC 7240 mm–3, Hb
6.7  g/dL, Ht 22.1, PLT 118,000 mm–3)
“Breakthrough”
Disseminated skin
lesions  + respiratory distress
Chest  radiogram: Pleural empyema
Pleural  ﬂuid: “Aerobic nocardiform
actinomycetes
ESR  63 mm/h, CRP 21.6 mg/dL
Imipenem 2 g/day + amikacin
1  g/day + doxycycline 200 mg/day
Surgical: drainage and debridement
45th  ⇒ 90th days Resolution of cutaneous lesions and
empyema
Scarred cutaneous lesions ESR 38 mm/h, CRP 0.65 mg/dL Amikacin 1 g/day + doxycycline
200  mg/day
3rd  ⇒ 4th months Relapse
High fever, new nodules ESR 85 mm/h, CRP 5.2 mg/dL Imipenem 2 g/day + amikacin
1  g/day + vancomycine 2 g/day
4th ⇒ 6th months Suppression or cure
Discharge  from hospital
None ESR 45 mm/h, CRP 0.66 mg/dL Doxycycline 200 mg/day 6th ⇒ 7th months Re-activation
Arthritis (right knee and ankle) ESR 95 mm/h,
CRP  21 mg/dL
Ceftriaxone  2 g/day + amikacin
1  g/day + doxycycline 200 mg/day
7th ⇒ 9th months Hospitalization
No response, new symptoms
New nodules formation
(subclavian  catheter region)
ESR  104 mm/h, WBC 8800 mm–3, Hb
12.7  g/L, CRP 14.7 mg/dL
Linezolid 1200 mg/day + doxycycline
200  mg/day
9th  ⇒ 12th months Suppression or cure + adverse effects due
to  linezolid
Peripheric neuropathy, severe
malaise
ESR  42 mm/h,
CRP  1.06 mg/dL
TMP/SXT  5 mg/kg/day + doxycycline
200  mg/day + B6 vitamin
12th  ⇒ 15th months Resolution discharge from hospital (13th
month)
Fluctuating mild cutaneous
symptoms
ESR  26 mm/h, Hb g/L, Ht 39.8, CRP
0.73 mg/dL
TMP/SXT  5 mg/kg/day + doxycycline
200  mg/day
15th  ⇒ 22nd months Resolution and cure
None ESR 10 mm/h,
WBC  8080 mm–3, Hb 14.2 g/L, Ht 43.1
CRP  0.3 mg/dL
TMP/SXT  5 mg/kg/day + doxycycline
200  mg/day
22nd  ⇒ 28th months Well-being
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efotaxime, ceftriaxone, cefepime, imipenem, vancomycin,
rimethoprim/sulphamethoxazole (TMP/SXT), minocycline,
oxycycline, and linezolid. Disk susceptibility test was per-
ormed  according to Boiron and Provost.5 Empyema  of the
horax  was  diagnosed by chest radiograph and chest com-
uted  tomography (CT). Further tests did not reveal any
vidence  of an underlying immunocompromised state.
reatment  and  clinical  outcome
eftizoxime and clindamycin combination (two weeks) were
witched  to TMP/SXT plus imipenem (one month) for treating
ne  of those fastidious microorganisms including Rhodococcus,
ocardia, Actinomyces, Peptococcus, etc., which was  suspected as
 causative agent based on the Gram smear. Surgical debride-
ent  of the dorso-thorocal lesions and surgical drainage of the
eft-sided  and then the right-sided empyema  ﬂuid were  also
mplemented in addition to medical therapy. Bone marrow
uppression due to TMP/SXT with a 10 mg/kg/day trimetho-
rim  dose had developed. The targeted antibiotic therapy to
he isolated Nocardia was  then a combination of imipenem,
mikacin, and doxycycline for 45 days. The response to this
egimen  was  good. As maintenance therapy amikacin plus
oxycycline  (one month) was  given but this regimen had failed
nd  the disease symptoms reactivated with high fever and
ew  nodules’ formation. Therapy was  discontinued after six
onths and the patient discharged from the hospital. Mainte-
ance  therapy with doxycycline monotherapy was  prescribed.
pproximately a month later the disease recurred with symp-
oms  of arthritis and followed by high fever and cutaneous
odules. Neither resolution nor progression of symptoms was
bserved  by combining ceftriaxone, amikacin, and doxycy-
line  for two additional months. After nine months from
nitiation  of disease symptoms linezolid, a drug not on the
arket  at that time, in combination with doxycycine was
tarted.  Clinical cure of the disease was  obtained after line-
olid  therapy for three months but eradication of the organism
ould  not be achieved due to cessation of linezolid, because of
igniﬁcant  adverse effects (ESR and CRP levels decreased to
6  mm/h  from 104 mm/h  and to 0.73 mg/dL from 14.7 mg/dL,
espectively). Mild relapsing episodes of cutaneous lesions
ere  treated with TMP/SXT (5 mg/kg/day) and doxycycline for
en more  months till no remission and the same antimicro-
ial  combination was  further lengthened for six more  months
fter  resolution of all disease symptoms with no side effects.
he  overall treatment course was  28-month long. The patient
emained  healthy and had no signs of relapse after being
ollowed-up for additional three years without therapy.
eﬁnitions
isseminated nocardiosis was  deﬁned as nocardia infection in
wo or more  non-contiguous sites. Breakthrough nocardiosis
as  deemed when a recurrent nocardial infection occurredn  a patient receiving systemic antibacterials with known
n  vitro activity against Nocardia spp. Relapse or reactivation of
he  disease was  noted when an initial improvement was fol-
owed  by reappearance of clinical symptoms and laboratory
ndings.64;1 8(5):556–560  559
Discussion
The literature survey of post-treatment follow-up of Nocardia
infections  is often too brief or unknown, making the ultimate
success  of therapy uncertain.7 Members of the N. asteroides
complex are more  frequently involved in pulmonary infec-
tions.  Recently, several new species have been described in
this  complex. The present report is a case of disseminated
persistent infection in an immunocompetent patient with pri-
mary cutaneous involvement, empyema, and arthritis due to
N. cyriacigeorgica, which was  formerly part of the N. asteroides
complex. Previous cases of N. cyriacigeorgica infections have
been  reported in immunocompromised patients.8,9
The experience with nocardiosis suggests that when the
infection  is disseminated, the clinical response is slow.10
Therefore successful therapy requires combination of antimi-
crobial  drugs and appropriate surgical drainage. The optimal
antimicrobial therapy depends on the severity and localization
of  the infection, the species of Nocardia, host immune status,
potential  drug interactions, toxicity associated with antibiotic
usage,  and duration of illness prior to diagnosis.1,2,11
Imipenem and amikacin seemed to be the most effective
agents, and in vitro synergism has been demonstrated between
imipenem  and TMP/SXT, imipenem and cefotaxime, amikacin
and  TMP/SXT.1,2,12,13 Although synergy has been reported in
the  literature, Kanemitsu et al.14 described that synergy was
present  in 83% of 23 N. asteroides strains treated with amikacin
and  TMP/SXT, in 26% of 15 strains treated with amikacin plus
ceftriaxone,  and in 5% of 26 tests conducted with amikacin
and  imipenem, thus showing that synergic effect of antimi-
crobial  combinations were not observed in all cases. In the
present  case, combination therapy with imipenem, amikacin,
and  doxycycline did not improve disease outcome unless van-
comycin was  added.
New  antimicrobial agents are needed. The relatively high
incidence  of adverse events, such as diffuse rash and myelo-
suppression occurrence during sulfonamide therapy, has been
reported. Besides, there is lack of alternative highly active
oral  agents.1,2,14 Linezolid is the ﬁrst antimicrobial to be
active against all clinically signiﬁcant species of the genus
Nocardia.14,15 It has been reported to be effective in treatment,
especially in disseminated disease. Because of its activity
and  availability as an oral agent and the current limitations
of  the sulfonamides, linezolid has the potential to be the
primary  drug of choice for treating Nocardia disease.16 Treat-
ment  related anemia and peripheral neuropathy have been
reported,16 which resolved when linezolid therapy is discon-
tinued,  as observed in the present case.
Remissions and exacerbations lasting for days or weeks
are  characteristic of the disease.11,17,18 The disease may
spread hematogenously leading to long-term persistent
nocardiosis.18 In the absence of consensus on the length of
therapy,  investigators mostly recommend to prolong medica-
tion  between 6 and 24 months because of the relapsing nature
of  the infection.6,19 Further progression of cutaneous disease
to  empyema  and arthritis, “breakthrough nocardiosis” under
combined  therapy was  seen in the present case. Therefore,
treatment duration of 28 months was  the longest reported
period  in the literature.
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19.  Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines560  b r a z j i n f e c t d 
The sequence of different combined antibiotics used, for
so  long in this patient might have implications for managing
similar  cases in the future. Antibiotics with intracellular activ-
ity  may  be beneﬁcial in long-term treatment of the disease. As
there are no unanimous guidelines on the therapy of nocardia
infections, at the moment the optimal duration of treatment
is  uncertain and requires expertise.
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